C6DB59E1-4D60-4B22-9417-CD1D044B75E8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.203679369250985
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.448
- CHOLESTEROL_HOMEOSTASIS+0.391
- INTERFERON_ALPHA_RESPONSE+0.385
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.366
- UV_RESPONSE_UP+0.324
- NOTCH_SIGNALING+0.307
- MITOTIC_SPINDLE+0.287
- ADIPOGENESIS+0.283
- MTORC1_SIGNALING+0.281
- HEDGEHOG_SIGNALING+0.268
Top 10 suppressed
- ANGIOGENESIS-0.480
- COAGULATION-0.347
- IL6_JAK_STAT3_SIGNALING-0.274
- ALLOGRAFT_REJECTION-0.272
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.262
- SPERMATOGENESIS-0.197
- INFLAMMATORY_RESPONSE-0.169
- COMPLEMENT-0.156
- MYOGENESIS-0.131
- IL2_STAT5_SIGNALING-0.098
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7B6D13EE-FE13-4BA8-BA65-1A10307A7936 | — | — | 0.874 |
| 2 | 387C53ED-A9ED-481F-87D9-87090B690E0E | — | — | 0.870 |
| 3 | AE988295-3046-4778-81C5-B787CAC92268 | — | — | 0.851 |
| 4 | 3A2D0D6F-66C3-48EE-9EA4-68668FF9B043 | — | — | 0.801 |
| 5 | A0DA6087-9D43-41F9-8569-9F9320E4A9E8 | — | — | 0.783 |
| 6 | D1BFDB5B-3131-4B5C-8090-B3B91D4450F3 | — | — | 0.762 |
| 7 | 077523A7-E1C9-4E9F-8C9F-B9F647B4DF7C | — | — | 0.753 |
| 8 | 8AACDB46-9BB3-42BA-871D-7A593F14430A | — | — | 0.751 |
| 9 | 3DC38276-A6D2-49C6-8F54-3F50F6BFAD0C | — | — | 0.743 |
| 10 | BS_G3RJTBZD | high-grade glioma | — | 0.735 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.448 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.391 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.385 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.366 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.324 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.307 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.287 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.283 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.281 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.268 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.267 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.248 | Inavolisib | — uncovered |
| PEROXISOME | 0.241 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.235 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.217 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.214 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.186 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.174 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.157 | Idelalisib | — uncovered |